Kirsten Heimann, J. Grant Collins, F. Richard Keene et al.
RNA and DNA binding of inert oligonuclear ruthenium(II) complexes in live eukaryotic cells
RNA and DNA binding of inert oligonuclear ruthenium(II) complexes in live eukaryotic cells

Xin Li, Anil K. Gorle, Tracy D. Ainsworth, Kirsten Heimann, Clifford E. Woodward, J. Grant Collins and F. Richard Keene

Confocal microscopy was used to study the intracellular localisation of a series of inert polypyridylruthenium(II) complexes with three eukaryotic cells lines – baby hamster kidney (BHK), human embryonic kidney (HEK-293) and liver carcinoma (Hep-G2). Co-staining experiments with the DNA-selective dye DAPI demonstrated that the di-, tri- and tetra-nuclear polypyridylruthenium(II) complexes that are linked by the bis[4(4'-methyl-2,2'-bipyridyl)-1,12-dodecanediamine bridging ligand ("bb12") showed a high degree of selectivity for the nucleus of the eukaryotic cells. Additional co-localisation experiments with the general nucleic acid stain SYTO 9 indicated that the ruthenium complexes showed a considerable preference for the RNA-rich nucleolus, rather than chromosomal DNA. No significant differences were observed in the intracellular localisation between the ΔΔ and ΛΛ enantiomers of the dinuclear complex. Cytotoxicity assays carried out over 72 hours indicated that the ruthenium complexes, particularly the tri- and tetranuclear species, were significantly toxic to the eukaryotic cells. However, when the activity of the least cytotoxic compound (the ΔΔ enantiomer of the dinuclear species) was determined over a 24 hour period, the results indicated that the ruthenium complex was approximately a 100-fold less toxic to liver and kidney cells than to Gram positive bacteria. Circular dichroism (CD) spectroscopy was used to examine the effect of the ΔΔ and ΛΛ enantiomers of the dinuclear complex on the solution conformations of RNA and DNA. The CD experiments indicated that the RNA maintained the A-type conformation, and the DNA the B-type structure, upon binding by the ruthenium complexes.

Introduction

There has been significant interest over the last forty years in the non-covalent interactions of inert transition metal complexes with DNA and RNA.1–3 In particular, the nucleic acid binding properties of ruthenium(II) complexes containing polypyridyl ligands have been extensively studied.4–8 These metal complexes have a rigid octahedral framework and can interact with nucleic acids through a variety of different modes, with the particular mode of binding being predictably governed by the metal complex structure. Furthermore, the structure of a ruthenium(II) complex can be readily modified – e.g. shape, charge, or the addition of specific recognition elements – to “tune” nucleic acid binding. Additionally, and if applicable, the chirality of the ruthenium complex can also be used to gain even greater control over the specificity or selectivity of the binding.

More recently, due to the nucleic binding properties of inert polypyridylruthenium(II) complexes, there has been increasing interest in their biological properties.9–16 A variety of mononuclear and dinuclear complexes have shown good in vitro anticancer activity, which is generally considered to be due to DNA binding. However, in some cases other mechanisms of action have been proposed – e.g. interactions with membranes or mitochondrial-mediated apoptosis.15 In addition to the established anticancer properties of inert polypyridylruthenium(II) complexes, there is now growing recognition of their potential as antimicrobial agents. Antimicrobial resistance is an increasingly serious threat to global public health: infections caused by antibiotic-resistant bacteria are associated with increased morbidity and mortality.17 The lack of new antimicrobials in the pipeline to replace those in

*School of Physical, Environmental and Mathematical Sciences, University of New South Wales, Australian Defence Force Academy, Canberra, ACT 2600, Australia. E-mail: g.collins@adfa.edu.au

**ARC Centre of Excellence for Coral Reef Studies, James Cook University, Townsville, QLD 4811, Australia

^College of Marine & Environmental Sciences, James Cook University, Townsville, QLD 4811, Australia. E-mail: kirsten.heimann@jcu.edu.au

^Centre for Biodiscovery and Molecular Development of Therapeutics, James Cook University, Townsville, QLD 4811, Australia

^Department of Matter & Materials, College of Science, Technology & Engineering, James Cook University, Townsville, QLD 4811, Australia

°School of Chemistry and Physics, University of Adelaide, Adelaide, SA 5005, Australia. E-mail: richard.keene@adelaide.edu.au
current use which are becoming ineffective has fostered research into the development of new types of drugs.

Dwyer and co-workers initially demonstrated the antimicrobial activity of mononuclear polypyridylruthenium(II) complexes against both Gram negative and Gram positive bacteria. We have subsequently shown that dinuclear analogues have even greater antimicrobial potential: \([\text{Ru}(\text{phen})_2(\mu-\text{bb}_n)_2]^4+\) ("Rubb\(_n\); where phen = 1,10-phenanthroline; \text{bb}_n = \text{bis}[4(4'-methyl-2,2'-bipyridyl)]-1,\,n-\text{alkane} for \(n = 5, 7, 10, 12\) and 16 – see Fig. 1) showed excellent activity, and they maintained the activity against drug-resistant strains such as methicillin-resistant \textit{Staphylococcus aureus} (MRSA). Furthermore, preliminary toxicity assays against human red blood cells and a human white blood leukemia cell line (THP-1) demonstrated that the Rubb\(_n\) complexes were not toxic to human cells at the concentrations required to kill the bacteria.

While the affinity of polypyridylruthenium(II) complexes for nucleic acids can be readily demonstrated \textit{in vitro}, it is more important to establish nucleic acid binding in live cells at concentrations similar to those required for anticancer or antimicrobial activities. Although there have been relatively few cellular localisation studies of polypyridylruthenium(II) complexes, the results reported to date have demonstrated a surprisingly diverse range of binding sites in eukaryotic cells. For example, Svensson et al. showed that the cellular localisation of a series of ruthenium dipyridophenazine (dppz) complexes in Chinese hamster ovarian cells was dependent upon the relative lipophilicity. The least lipophilic complex was predominantly found in the nucleus and the most lipophilic accumulated outside of the nucleus and probably in the endoplasmic reticulum. Furthermore, Gill et al. demonstrated that the DNA groove-binding dinuclear complex \([\text{Ru(phen)}_2]_{2+}\) (where \text{phen} = 1,10-phenanthroline; \text{tpphz} = tetrpyridophenazine) could be used to image nuclear DNA in eukaryotic cells. Alternatively, the 4,7-diphenyl-1,10-phenanthroline analogue \([\text{Ru(DIP)}_2]_{2+}\) localised in the endoplasmic reticulum. By contrast, the Rubb\(_n\) complexes were shown to localise in the mitochondria of L1210 white blood cells. Mitochondrial targeting has also been observed for other ruthenium complexes.

As preliminary pharmacokinetic studies indicated that the Rubb\(_n\) complexes accumulate in the liver and kidney of mice, we sought to confirm that the ruthenium complexes localised in the mitochondria of liver and kidney cells as we had previously demonstrated with the L1210 cells. In the present study, we examined the localisation of Rubb\(_{12}\) and its tri- and tetra-nuclear analogues in liver and kidney cells by confocal microscopy. In order to examine the effect of the ruthenium complexes on large DNA and RNA molecules, we also studied the binding of the ruthenium complexes to calf thymus DNA and baker’s yeast RNA by CD spectroscopy. Interestingly, Rubb\(_{12}\) was found to selectively accumulate in the nucleolus, the RNA-rich component of the nucleus, rather than in the mitochondria.

**Experimental**

**Synthesis of ruthenium(II) complexes**

The ruthenium complexes used in this study were synthesised and characterised as previously described.

**Cell culture**

The BHK (baby hamster kidney) cell line and two human cell lines – HEK-293 (embryonic kidney) and Hep-G2 (liver carcinoma) – were used in this study. All cell lines were generously supplied by Australian Army Malaria Institute (AMI, Enoggera, QLD, Australia), and originated from the American Type Culture Collection (ATCC, Manassas, VA). All cell lines were cultured in 75 mL culture flasks in RPMI-1640 (Roswell Park Memorial Institute 1640; Sigma-Aldrich) media supplemented with 10% fetal bovine serum (Sigma-Aldrich), 4 mM l-glutamine (Sigma-Aldrich) and 1.5 g L\(^{-1}\) sodium bicarbonate (Sigma-Aldrich) at 37 °C in an atmosphere of 5% humidified CO\(_2\). Cells used in the study were in the logarithmic growth phase. Cells were grown to 70% confluency, and then trypsinised with 0.25% trypsin–0.02% EDTA (Sigma-Aldrich).

**Cytotoxicity**

The cytotoxicities of the ruthenium complexes were determined using the Alamar Blue cytotoxicity assay as previously described. All data were from at least three independent experiments and the IC\(_{50}\) determined using GraphPad Prism 6.0 (GraphPad Software, San Diego, USA).

**Incubation of cells with ruthenium(II) complexes and organelle stains**

The trypsinised cells were seeded on the coverslips in petri dishes. The ruthenium complexes were applied to the cells in RPMI-1640 media to make the desired concentration (arranged from 5 to 50 \(\mu\)M) and incubated at 37 °C with 5% CO\(_2\) for 4 h or overnight as described. During the final 30 min of incubation, 100 nM Mitotracker® Green FM (Invitrogen) was added for mitochondrial staining, 100 nM DAPI (4',6-diamidino-2-phenylindole; Invitrogen) for nuclear staining and 50 nM SYTO 9 for nucleolus staining, and the cells incubated for a further 5 min. The coverslips were rinsed gently with phosphate buffer solution and mounted on bridged slides for imaging.

![Fig. 1](Image)

**Fig. 1** The structure of the dinuclear Rubb\(_n\) complexes, for \(n = 5, 7, 10, 12\) and 16.
Cellular localisation studies

The cellular localisation of the ruthenium(II) complexes was determined using a Zeiss laser scanning confocal microscope (LSM 700). Samples were viewed under a 40× or 63× oil immersion lens. Metal complexes ($\lambda_{\text{ex}} = 450$ nm, $\lambda_{\text{em}} = 610$ nm) and Mitotracker Green FM ($\lambda_{\text{ex}} = 490$ nm, $\lambda_{\text{em}} = 516$ nm) were excited using blue argon laser ($\lambda_{\text{ex}} = 488$ nm), and emissions were collected at 570–650 nm and 470–550 nm, respectively. For DAPI excitation, diode laser ($\lambda_{\text{ex}} = 405$ nm) was used and the emission detected at 430–500 nm. SYTO9 was excited with $\lambda_{\text{ex}} = 488$ nm, and the emission collected at 495–510 nm. Image data acquisition and processing were performed using Zen software 2009 (Carl Zeiss).

CD spectroscopy

Solutions of CT-DNA (Sigma Aldrich) in phosphate buffer (650 μL, 1 mM Na2EDTA, 10 mM Na2HPO4, 20 mM NaCl, pH 7.0) gave a ratio of UV absorbances at 260 and 280 nm, $A_{260}/A_{280}$ of 1.80–1.90, indicating that the DNA was sufficiently free from protein. The concentration of CT-DNA stock solution was determined from UV absorption at 260 nm. The circular dichroism spectral titration experiments were performed by keeping the CT-DNA concentration constant (2.7 mM bases) while varying the concentration of metal complexes from 0 to 39 μM. The CD spectra were measured in 1 mm path length quartz cuvettes on a JASCO J-815 circular dichroism spectrometer. Two scans were accumulated at a scan speed of 100 nm min$^{-1}$. All CD spectra were recorded at every 0.5 nm from 200 to 350 nm. Sample temperature was maintained at 35 °C using a JASCO MCB-100 mini-circulation bath. Spectra were corrected for buffer signal.

The baker’s yeast RNA (Sigma Aldrich) stock solution was also prepared in phosphate buffer in DEPC (Sigma Aldrich) treated water. The $A_{260}/A_{280}$ value was 2.10, indicating the RNA was pure. The initial RNA concentration was 2.3 mM (bases). The titration of ruthenium complexes and the data collection were the same as indicated for the DNA experiments.

Results

Based upon our previous studies on the antimicrobial activities and the corresponding toxicities to eukaryotic cell lines, Rubb$_{12}$ appears to have the best therapeutic window (antimicrobial activity compared to toxicity) of the dinuclear complexes. Furthermore, the tetranuclear analogue Rubb$_{12}$-tetra (see Fig. 2) has the best antimicrobial activity of all the oligonuclear ruthenium complexes we examined. Consequently, this study focused on the Rubb$_{12}$, Rubb$_{12}$-tri and Rubb$_{12}$-tetra complexes, and in order to examine the effect of the chirality of the complexes, we examined the toxicity, cellular localisation and DNA/RNA binding of the $\Delta\Delta$ and $\Lambda\Lambda$ enantiomers of Rubb$_{12}$.

In vitro toxicity against kidney and liver cells

In order to determine the biologically relevant concentrations of the ruthenium complexes, and to ascertain the toxicity of the tri- and tetra-nuclear species against eukaryotic cells for the first time, the IC$_{50}$ values of Rubb$_{12}$, Rubb$_{12}$-tri and Rubb$_{12}$-tetra were determined against three cell lines (BHK, HEK-293 and Hep-G2). The results are summarised in Table 1. All ruthenium complexes were toxic against the three cell lines, particularly the cancer cell line Hep-G2. The dinuclear complexes $\Delta\Delta/\Lambda\Lambda$-Rubb$_{12}$ were less toxic than Rubb$_{12}$-tri, which was slightly less toxic than Rubb$_{12}$-tetra. For Rubb$_{12}$, there were only small differences in the IC$_{50}$ values for the $\Delta\Delta$ and $\Lambda\Lambda$ enantiomers.

Fig. 2 Structures of the trinuclear (Rubb$_{12}$-tri) and tetranuclear (Rubb$_{12}$-tetra) ruthenium(II) complexes.
Table 1  72 hour-IC₅₀ values (µM) against the BHK, HEK-293 and Hep-G2 cell lines, and the minimum inhibitory concentration (MIC; µM) against S. aureus and E. coli for the ruthenium complexes

|           | BHK | HEK-293 | Hep-G2 | S. aureus | E. coli |
|-----------|-----|---------|--------|-----------|---------|
| ΔΔ-Rubb12 | 54.3 ± 3.2 | 15.1 ± 2.8 | 5.2 ± 2.0 | 0.6 | 2.5 |
| AA-Rubb12 | 47.8 ± 2.7 | 14.3 ± 3.4 | 9.8 ± 0.3 | 1.2 | 2.5 |
| Rubb₂-tetra | 21.1 ± 1.7 | 8.8 ± 0.7 | 7.4 ± 3.8 | 0.4 | 1.6 |
| Rubb₂-tetra | 13.1 ± 1.9 | 6.4 ± 1.4 | 5.2 ± 1.3 | 0.3 | 1.2 |

Table 2  Comparison of the toxicities of the ruthenium complexes to the BHK, HEK-293 and Hep-G2 cell lines to the antimicrobial activity against S. aureus and E. coli, the selectivity index (SI). SI is defined as the ratio of the IC₅₀ to the MIC

|           | BHK | HEK-293 | Hep-G2 | S. aureus | E. coli |
|-----------|-----|---------|--------|-----------|---------|
| ΔΔ-Rubb12 | 91  | 22      | 25     | 6         | 9       | 2    |
| AA-Rubb12 | 40  | 19      | 12     | 6         | 8       | 4    |
| Rubb₂-tetra | 53  | 13      | 22     | 6         | 19      | 5    |
| Rubb₂-tetra | 44  | 11      | 21     | 5         | 17      | 4    |

Table 3  IC₅₀ values (µM) of ΔΔ-Rubb₁₂ as a function of time against the BHK, HEK-293 and Hep-G2 cell lines

|        | 4 hour   | 8 hour   | 24 hour  | 48 hour  | 72 hour  |
|--------|----------|----------|----------|----------|----------|
| BHK    | 190.9 ± 36.5 | 103.8 ± 8.5 | 70.5 ± 26.4 | 57.5 ± 7.1 | 54.3 ± 3.2 |
| HEK-293 | 90.8 ± 17.9 | 90.48 ± 34.3 | 50.9 ± 19.9 | 24.9 ± 1.1 | 15.1 ± 2.8 |
| Hep-G2 | 103.2 ± 3.8 | 109.7 ± 29.3 | 61.7 ± 5.5 | 15.8 ± 10.4 | 5.2 ± 2.0 |

Cellular localisation study

Fig. 3 shows the comparison of the localisation of ΔΔ-Rubb₁₂ in BHK cells with the selective mitochondrial stain Mitotracker Green (20 hour incubation). It is clearly observed that ΔΔ-Rubb₁₂ does not localise in the mitochondria, but appears to preferentially accumulate in the cell nucleus, as shown by the results at 5 µM. Similar results were obtained with the other cell lines and the other ruthenium complexes (data not shown).

The localisation in the nucleus was confirmed through co-staining with DAPI. DAPI is considered to be a DNA-selective stain, as it binds DNA 100-fold more strongly than RNA and has a 3-fold higher fluorescence quantum yield when bound to DNA than to RNA.25 In Fig. 4 we show the results of the DAPI co-staining experiments with ΔΔ-Rubb₁₂ and BHK cells. The ΔΔ-Rubb₁₂ concentration was 50 µM (approx. IC₅₀) and the incubation time was 20 hours. These results confirm the preferential accumulation of the ruthenium complexes in the nucleus, however the localisation pattern was not identical. While significant DNA binding of the complex was observed at this concentration (as evidenced by the overlap with DAPI staining), there is also intense ΔΔ-Rubb₁₂ red fluorescence in areas of the nucleus where there is little or no DAPI fluorescence. These so-called “DAPI holes” are generally recognised as nucleoli.20 The nucleolus is the site within the nucleus where ribosomal-RNA (r-RNA) is synthesised, and consequently is rich in r-RNA. The nucleoli can be highlighted through staining with SYTO 9. This general nucleic acid stain binds both DNA and RNA but binds RNA with greater affinity. The results of SYTO-9 co-staining experiments (also shown in Fig. 4) confirmed that ΔΔ-Rubb₁₂ does accumulate in the nucleoli.

As is observed in Fig. 4, there is considerable DNA co-staining at 50 µM; however, at 10 µM there appears to be predominant RNA binding, and almost exclusive RNA binding at 5 µM (see Fig. 3).

Similar results were obtained with the other eukaryotic cell lines. For example, Fig. 5 shows the preferential accumulation of ΔΔ-Rubb₁₂ in the nucleoli of Hep-G2 cells.

No significant difference in the localisation of ΔΔ-Rubb₁₂ and AA-Rubb₁₂ enantiomers was observed. Similarly, for the Rubb₂-tetra and Rubb₂-tetra complexes the same pattern of localisation was observed; however, the total accumulation appeared to be greater with more DNA binding observed for the Rubb₂-tetra and Rubb₂-tetra complexes.
Fig. 3  Left to right – Co-localisation of Mitotracker Green (green) and ΔΔ-Rub12 (red) in BHK cells at different concentrations: top panel, 10 μM and bottom panel, 5 μM. The overlays are shown on the right. Scale bar = 10 μm.

Fig. 4  Rubb12 localisation in BHK cells at 50 μM (20 hour incubation), stained with DAPI (blue; top left), SYTO 9 (cyan; top right), ΔΔ-Rub12 (red; bottom left) and merged (bottom right), where the white colouration arises from co-localisation of SYTO 9 and ΔΔ-Rub12, and magenta colouration from co-localisation of DAPI and ΔΔ-Rub12. Scale bar = 10 μm.
Furthermore, increased accumulation was also observed outside of the nucleus (Fig. 6).

To examine the effect of time on the localisation of ΔΔ-Rubb\(_{12}\), BHK cells were incubated with ΔΔ-Rubb\(_{12}\) at 55 \(\mu\)M for both 4 and 20 hours. The resultant images are shown in Fig. 7. After a 4 hour incubation, ΔΔ-Rubb\(_{12}\) was localised to a greater extent in the cytoplasm compared to nucleolus. Subsequently, after the longer incubation time, the ΔΔ-Rubb\(_{12}\) was predominantly observed in the nuclear region, particularly in the nucleolus and nuclear envelope. These observations suggest that the ruthenium complexes will accumulate in the endoplasmic reticulum after passing through the cell membrane, but finally accumulate in the nucleolus. Similar results were obtained with ΛΛ-Rubb\(_{12}\) (data not shown).

**CT-DNA binding**

While the confocal microscopy experiments demonstrated that the Rubb\(_n\) complexes bound RNA and DNA in live cells, the effect of the ruthenium complexes on the solution conformation of the nucleic acids is unknown. In order to examine the effect of micro-molar concentrations of the ruthenium complexes on the solution conformation of large segments of DNA and RNA, an *in vitro* binding study with ΔΔ- and ΛΛ-Rubb\(_{12}\) was conducted by circular dichroism spectroscopy.
In a CD spectrum, B-form CT-DNA is characterised by a positive band at 260–280 nm due to base stacking and a negative band around 245 nm due to the helicity of the structure. However, the enantiomers of Rubb also have strong CD signals in the 200–300 nm range. Consequently, DNA binding was determined by comparing the observed signal upon titration of ΔΔ- or ΛΛ-Rubb into the CT-DNA sample with the arithmetic sum of the individual CD spectra of the metal complex and DNA.

Addition of both ΔΔ- and ΛΛ-Rubb induced significant decreases in the CD signal for the CT-DNA with added ruthenium complex in the 260–300 nm range at concentrations below the IC50 values (Fig. 8). However, and most clearly seen for the titration with ΛΛ-Rubb, the basic B-type conformation is maintained (negative peak at 245 nm and positive peak at 260–280 nm). The decrease in intensity of the CD signal between 260 and 300 nm is consistent with the changes noted for the addition of high concentrations (5 M) of NaCl to CT-DNA – a decrease in the CD signal between 260 and 300 nm caused by high salt concentration is generally interpreted as the DNA structure becoming more tightly wound, but remaining in the B conformation.

RNA binding

The binding of ΔΔ- and ΛΛ-Rubb to RNA was examined by CD spectroscopy in an analogous manner to the study described for DNA. The CD spectrum of free RNA at 35 °C has two positive bands at 225 and 270 nm and two negative bands at 210 and 230 nm, which is consistent with the double-stranded A-conformation. The large reduction in the CD signal at 260–280 nm upon addition of either ΔΔ- or ΛΛ-Rubb indicates that both enantiomers interact strongly with RNA at concentrations below the IC50 values (see Fig. 9). This band is sensitive to base-stacking; consequently, the decrease in its intensity can be interpreted as a modification of base-stacking that potentially partially destabilises the A-type conformation. Consistent with this interpretation is the decrease in the base-stacking band observed for RNA oligonucleotides upon lowering the ionic strength of the solution from 1 M to 0.01 M NaCl. Importantly, the CD results indicate that the ruthenium complex-bound RNA maintains the A-type structure.

Discussion

The results of this study indicate that the oligonuclear inert ruthenium complexes linked by the bb ligand are toxic to kidney and liver cells. However, even when comparing the 72 hour cytotoxicity data with the 16–18 hour antimicrobial MIC values, it is clear that the ruthenium complexes are more toxic to bacteria than the eukaryotic cells examined in this study. For the BHK and HEK-293 cell lines, the dinuclear...
complex was less toxic than the tri- and tetra-nuclear species, and showed the largest relative (and absolute) difference between cytotoxicity and antimicrobial activity. Toxicity is related to the cellular uptake. The lower toxicity of the dinuclear complex is possibly due to its lower lipophilicity, with the log \( P \) values for Rubb\(_{12}\), Rubb\(_{12}\)-tri and Rubb\(_{12}\)-tetra being \(-2.9, -1.0\) and \(-1.6\) respectively.\(^{25}\) Interestingly, even though the trinuclear species is more lipophilic than the tetranuclear complex, it was generally less toxic to the eukaryotic cells. This demonstrates the importance of the cationic charge of the ruthenium complex in the mechanism of the observed toxicity towards eukaryotic cells.

Confocal microscopy was used to determine the cellular localisation of the ruthenium complexes in the three cell lines. By comparison with DAPI and SYTO 9 staining, it was concluded that Rubb\(_{12}\), Rubb\(_{12}\)-tri and Rubb\(_{12}\)-tetra preferentially accumulated in the nucleolus at low complex concentrations, while significant DNA binding is also observed at higher concentrations. The preference for RNA is consistent with our previous study that Rubb\(_{12}\) targets the nucleolus in Hep-G2 cells.\(^{9}\) The overall preference of these complexes to the nucleus is unsurprising given the mitochondrial selectivity we observed for the Rubb\(_{n}\) complexes in L1210 cells.\(^{1,2}\) Also of note is the difference between the rigidly linked tetrapyrido-phenazine (tpphz) dinuclear ruthenium complexes studied by Thomas and co-workers\(^{11,22}\) and the flexibly-linked bb\(_n\) complexes examined in this study. The less lipophilic [\[Ru(phen)\(_2\)]\(_2\)\(\mu\text{-tpphz}\)]\(^{4+}\) (log \( P \) = \(-0.96\)) targeted the nucleus, but not the nucleolus, and showed little toxicity towards MCF-7 cancer cells IC\(_{50}\) = 138 \(\mu\)M.\(^{11}\) On the other hand, the more lipophilic analogue containing the 4,7-diphenyl-1,10-phenanthroline ligand [\[Ru(DIP)\(_2\)]\(_2\)\(\mu\text{-tpphz}\)]\(^{4+}\) (log \( P \) = 1.52) targets the endoplasmic reticulum and is highly toxic to MCF-7 cells (IC\(_{50}\) = 7 \(\mu\)M).\(^{22}\) The bb\(_n\) linked oligonuclear complexes are less lipophilic but all show greater toxicity to the cell lines studied than [\[Ru(phen)\(_2\)]\(_2\)\(\mu\text{-tpphz}\)]\(^{4+}\), and despite the differences in log \( P \) values, all target the nucleolus. The results of this study suggest that in these cases log \( P \) values do not reflect the ease with which the ruthenium complexes can cross cell membranes. Although it is acknowledged that the [\[Ru(phen)\(_2\)]\(_2\)\(\mu\text{-tpphz}\)]\(^{4+}\) complexes enter cells by active transport,\(^{11}\) the results of this study suggest that the distance between the ruthenium centres (compared to the length of the highly non-polar section of a lipid bilayer) could be a more important factor for cellular uptake than lipophilicity, per se.

The CD spectroscopy experiments confirmed that Rubb\(_{12}\) can interact with DNA and RNA at biologically relevant concentrations. While the CD results suggested that Rubb\(_{12}\) affected the base-stacking of both DNA and RNA, there was no indication that the ruthenium complex condensed or aggregated either nucleic acid at \(\text{IC}_{50}\) concentrations. Furthermore, both the RNA and DNA maintained their normal solution conformations upon \(\Delta\Delta/\Lambda\Lambda\)-Rubb\(_{12}\) binding. Given the preferential RNA binding exhibited by the ruthenium complexes, it is possible that RNA binding is responsible for the cellular toxicity. In support of this proposal is the observation that after 4 hours incubation with BHK cells, confocal microscopy indicated that a large proportion of the administered Rubb\(_{12}\) was located outside of the nucleus, but after 20 hours nearly all the ruthenium complex was inside the nucleus in the nucleolus. The IC\(_{50}\) value after a 4 hour incubation in the BHK cells was 190.9 \(\mu\)M, but this dropped to 70.5 \(\mu\)M after 24 hours and then only decreased to a small extent over the next 48 hours.

The results of this study indicate that the oligonuclear ruthenium complexes do bind nucleic acids in live cells, thereby supporting the proposed biological potential suggested in the many studies of nucleic acid binding by cationic transition metal complexes.\(^{1-8}\) However, it appears the ruthenium complexes target RNA rather than DNA. We have previously demonstrated that the bulky dinuclear ruthenium complexes bind in the DNA minor groove and preferentially target non-duplex features, such as bulges and hairpin loops, compared to standard duplex structures.\(^{38,39}\) It could be argued that RNA contains a greater proportion of non-duplex structures than does DNA. However, generally only a slight difference was seen between the \(\Delta\Delta\) and \(\Lambda\Lambda\) enantiomers in terms of toxicity, intracellular localisation or in binding to long segments of DNA or RNA. In particular, a relatively larger enantiomeric effect is seen for Hep-G2 and S. aureus. As we have observed differences in the way the enantiomers interact

---

**Fig. 9** CD spectra of RNA and upon the addition of \(\Delta\Delta\)-Rubb\(_{12}\) (left) or \(\Lambda\Lambda\)-Rubb\(_{12}\) (right) at a concentration of 39 \(\mu\)M. The black line is the spectrum for RNA, the dashed line is the spectrum for the \(\Delta\Delta/\Lambda\Lambda\)-Rubb\(_{12}\), the blue line is the arithmetic sum of the individual CD spectra of the ruthenium complex and RNA, and the red line is the observed CD spectrum upon addition of the \(\Delta\Delta/\Lambda\Lambda\)-Rubb\(_{12}\) to the RNA.
with DNA oligonucleotides,\textsuperscript{7,38} it is possible that the effects observed in this study are primarily due to non-specific electrostatic interactions that cause sufficient structural modifications to inhibit RNA-driven transcription. The CD spectroscopy studies indicated that the ruthenium complex-bound DNA maintained the B-conformation, while the bound-RNA maintained the A-form. The A-form RNA has a shorter rise per base pair (≈2.8 Å) than B-DNA (≈3.4 Å).\textsuperscript{40} Consequently, A-RNA will have an increased linear negative charge density compared to B-form DNA. This should impact on the binding of polycations, and potentially when coupled to the increased proportion of more flexible non-duplex structures found in RNA, provides an explanation for the observed binding preference of the ruthenium complexes for RNA in the eukaryotic cells studied here.

In conclusion, the results of this study demonstrate that the Rubb\textsubscript{a} class of antimicrobial agents selectively accumulate in the nucleus of eukaryotic cells. However, the ruthenium complexes preferentially localise in the RNA-rich nucleoli, rather than with the chromosomal DNA. Although RNA and DNA binding is most likely responsible for the toxicity of the ruthenium complexes to the eukaryotic cells, the cytotoxicity assays indicated that the lead complex, ΔΔ-Rubb\textsubscript{12}, is approximately 100-fold less toxic to eukaryotic cells than to Gram positive bacteria.

**Acknowledgements**

We thank Professor Alan Baxter (Comparative Genomics Centre, James Cook University, Townsville, Australia) for the use of their laboratories and tissue culture facilities, and the Australian Army Malaria Institute (Enoggera, Queensland, Australia) for the donation of the cell lines.

**Notes and references**

1 S. J. Lippard, *Acc. Chem. Res.*, 1978, 11, 211.
2 B. Nordén, P. Lincoln, B. Akerman and E. Tuite, *Met. Ions Biol. Syst.*, 1996, 33, 177.
3 A. C. Komor and J. K. Barton, *Chem. Commun.*, 2013, 49, 3617.
4 K. E. Erkkila, D. T. Odom and J. K. Barton, *Chem. Rev.*, 1999, 99, 2777.
5 C. Metcalfe and J. A. Thomas, *Chem. Soc. Rev.*, 2003, 32, 215.
6 B. M. Zeglis, V. C. Pierre and J. K. Barton, *Chem. Commun.*, 2007, 4565.
7 R. F. Keene, J. A. Smith and J. G. Collins, *Coord. Chem. Rev.*, 2009, 253, 2021.
8 M. R. Gill and J. A. Thomas, *Chem. Soc. Rev.*, 2012, 41, 3179.
9 C. A. Puckett, R. J. Ernst and J. K. Barton, *Dalton Trans.*, 2010, 39, 1159.
10 C. A. Puckett and J. K. Barton, *Biochemistry*, 2008, 47, 11711.
11 M. R. Gill, J. Garcia-Lara, S. J. Foster, C. Smythe, G. Battaglia and J. A. Thomas, *Nat. Chem.*, 2009, 1, 662.
12 M. J. Pisani, P. D. Fromm, Y. Mulyana, R. J. Clarke, H. Korner, K. Heimann, J. G. Collins and F. R. Keene, *ChemMedChem*, 2011, 6, 848.
13 M. Matson, F. R. Svensson, B. Nordén and P. Lincoln, *J. Phys. Chem. B*, 2011, 115, 1706.
14 F. R. Svensson, J. Andersson, H. L. Åmand and P. Lincoln, *J. Biol. Inorg. Chem.*, 2012, 17, 565.
15 T. Chen, Y. Liu, W.-J. Zheng, J. Liu and Y.-S. Wong, *Inorg. Chem.*, 2010, 49, 6366.
16 M. R. Gill, H. Derrat, C. G. W. Smythe, G. Battaglia and J. A. Thomas, *ChemBioChem*, 2011, 12, 877.
17 H. W. Boucher, G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, L. B. Rice, M. Scheld, B. Spellberg and J. Bartlett, *Clin. Infect. Dis.*, 2009, 48, 1.
18 F. P. Dwyer, E. C. Gyafaras, W. P. Rogers and J. H. Koch, *Nature*, 1952, 170, 190.
19 F. P. Dwyer, I. K. Reid, A. Shulman, G. M. Laycock and S. Dixson, *Aust. J. Exp. Biol. Med. Sci.*, 1969, 47, 203.
20 F. Li, Y. Mulyana, M. Feterl, J. M. Warner, J. G. Collins and F. R. Keene, *Dalton Trans.*, 2011, 40, 5032.
21 F. R. Svensson, M. Matson, M. Li and P. Lincoln, *Biophys. Chem.*, 2010, 149, 102.
22 M. R. Gill, D. Cecchin, M. G. Walker, R. S. Mulla, G. Battaglia, C. Smythe and J. A. Thomas, *Chem. Sci.*, 2013, 4, 4512.
23 F. Li, *Inert dinuclear polypyridylruthenium(II) complexes as antimicrobial agents*, PhD thesis, University of New South Wales, Australia, 2013.
24 Y. Mulyana, D. K. Weber, D. P. Buck, C. A. Motti, J. G. Collins and F. R. Keene, *Dalton Trans.*, 2011, 40, 1510.
25 A. K. Gorle, M. Feterl, J. M. Warner, L. Wallace, F. R. Keene and J. G. Collins, *Dalton Trans.*, 2014, DOI: 10.1039/c4dt02139h.
26 J. O’Brien, I. Wilson, T. Orton and F. Pognan, *Eur. J. Biochem.*, 2000, 267, 5421.
27 S. Prakash, V. P. Vaidya, K. M. Mahadevan, M. K. Shivananda, P. A. Suchetan, B. Nirmala and M. Sunitha, *J. Chem. Pharm. Res.*, 2012, 4, 1179.
28 W. W. Wilfinger, K. Mackey and P. Chomczynski, *BioTechniques*, 1997, 22, 474.
29 F. A. Tanious, J. M. Veal, H. Buczk, L. S. Ratmeyer and W. D. Wilson, *Biochemistry*, 1992, 31, 3103.
30 D. Hernandez-Verdun, *The Nucleolus*, ed. M. O. J. Olson, Springer, New York, 2011, Ch. 1, pp. 3–28.
31 W. C. Johnson, CD of Nucleic Acids, in *Circular dichroism: principles and applications*, ed. K. Nakashii, N. Berova and R. W. Woody, VCH, New York, 1994, pp. 523–540.
32 J. Kypr, I. Kejnovská, D. Renclu and M. Vorlicková, *Nucleic Acids Res.*, 2009, 37, 1713.
33 M. Vorlicková, *Biophys. J.*, 1995, 69, 2033.
34 J. Kypr and M. Vorlicková, *Biopolymers*, 2002, 67, 275.
35 E. P. Loret, P. Georgel, W. C. Johnson Jr. and P. S. Ho, *Proc. Natl. Acad. Sci. U. S. A.*, 1992, **89**, 9734.
36 T. Kirihata, S. Nakano and N. Sugimoto, *Nucleic Acids Symp. Ser.*, 2004, **48**, 109.
37 F. Li, E. J. Harry, A. L. Bottomley, M. D. Edstein, G. W. Birrell, C. E. Woodward, F. R. Keene and J. G. Collins, *Chem. Sci.*, 2014, **5**, 685.
38 J. L. Morgan, C. B. Spillane, J. A. Smith, P. D. Buck, J. G. Collins and F. R. Keene, *Dalton Trans.*, 2007, **4333**.
39 F. Li, D. K. Weber, J. L. Morgan, J. G. Collins and F. R. Keene, *Dalton Trans.*, 2012, **41**, 6528.
40 S. A. Pabit, X. Qiu, J. S. Lamb, L. Li and S. P. Meisburger, *Nucleic Acids Res.*, 2009, **37**, 3887.